Neptune Stronger in Asia by Penetrating the Indian Market
06 June 2011 - 10:00PM
Neptune Technologies & Bioressources Inc. ("Neptune" or the
"Corporation") (Nasdaq:NEPT) (TSX-V:NTB) announces that it has
appointed Raj Nakra Associates as an agent for the Indian market.
Raj Nakra Associates already represents worldwide recognized brands
and brings along great knowledge of the Indian market within the
pharmaceutical industry, diatery supplement and functional food
industry. It has introduced several nutraceutical products in the
Indian market for the first time.
Neptune is continuously pursuing its growth worldwide and
emerging markets such as India will bring major contribution to
Neptune's future revenues. The Indian market is looked upon as very
promising with a GDP that has surpassed China's GDP for the very
first time in 2010. India as a society and culture has been at the
forefront of Alternative medicine for centuries.
''After evaluating different novel products to promote in India,
we came to the conclusion that Neptune Krill Oil stands above
all,'' stated Raj Nakra, Managing Director of Raj Nakra
Associates.
''Furthermore, we believe that Neptune Krill Oil will be very
well received in India. The country has over 300 million people in
middle class who are becoming increasingly aware of the need for
wellness and prevention rather than treatment of disease. Rising
rate of cardiac incidents in India is another major factor
propelling the growth of nutraceuticals and functional foods, which
promote heart health. As a matter of fact, we have already
received sizeable commitments from important players of the Indian
market for Neptune Krill Oil,'' added Raj Nakra.
''Looking at the growing pace of the Indian economy and the
Governmental focus on its desire to become a major and dominant
economic power within the democratic world has to capture one's
attention. Based on market analysis and forecast of Raj Nakra
Associates, we anticipate that India could represent as much as 15%
of Neptune overall revenues within the next 5 years,'' added Andre
Godin, CFO of Neptune.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that
are not statements of historical or current fact constitute
"forward-looking statements" within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995 and Canadian
securities laws. Such forward-looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could
cause the actual results of the Company to be materially different
from historical results or from any future results expressed or
implied by such forward-looking statements. In addition to
statements which explicitly describe such risks and
uncertainties, readers are urged to consider statements
labeled with the terms "believes," "belief," "expects," "intends,"
"anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that
are described from time to time in the Company's reports filed with
the Securities and Exchange Commission and the Canadian securities
commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group Contact:
Bob Beaty
(888) 221-0915
bob@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024